← Stocks · KYNB record
Signal record & history · Trifecta Signals
Kyntra has been flagged by the Trifecta screener 4 times since 2022. 1 signal confirmed; the median confirmed signal is down 98.7% since its Early Signal.
Price refreshes every trading day after the close.
Full interactive chart ↗ · partner link
Daily closes · through the most recent close
Price history from Jan 2018 · Signal tracking began Jan 2022
Headline statistics: confirmed signals only, measured from the confirmation price.
First signal Mar 2022 · Latest Jun 2023 · Confirmed 1 of 4 Early · Latest close in the chart data: Wed, Nov 4, 2026
Groups are mutually exclusive — every confirmed signal sits in exactly one.
Since March 2022, Kyntra has had four Early signals, one confirmed. Its one decided signal did not reach +10% within 90 days, and it did not finish ahead of the S&P 500 since confirmation. Three Early signals never confirmed and count in no statistic.
Every Early signal in the record, newest first.
Members see every signal below, and the group mix above.
Membership unlocks the complete signal timeline for KYNB and every other stock in the record — group tags, caution flags, and the full screener.
Already a member? Sign in and this page unlocks.
Kyntra Bio sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. With a market value of about $21 million, the company falls in the small-cap group.
The strongest run on Kyntra Bio’s record followed a confirmation in March 2022, falling about 33% over the following 90 days. Classification adds texture: its latest signal was rated Low Quality, revenue was shrinking by about 55% at the time, and it sat in the mid-cap group when that signal fired.
KYNB closed Wednesday, November 4 at $3.96, down 8.1% on the day. The last five sessions span about $3.96 to about $4.65.
